Scientific publications


Freijer, K., Volger, S., Pitter, J. G., Molsen-David, E., Cooblall, C., Evers, et al. (2018). Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group. Value in Health. [Available online 25 October 2018] Link

Begum M, Lewison G, Jassem J, Mixich V, Cufer T, Nurgozhin T, Shabalkin P, Kutluk T, Voko Z, Radosavljevic D, Vrdoljiak E, Eniu A, Walewski J, Aggarwal A, Lawler M, Sullivan R. Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. Eur J Cancer. 2018 Oct 19;104:127-136. doi: 10.1016/j.ejca.2018.08.024. [Epub ahead of print] Link

Rutten-van Mölken M, Leijten F, Hoedemakers M, Tsiachristas A, Verbeek N, Karimi M, Bal R, de Bont A, Islam K, Askildsen JE, Czypionka T, Kraus M, Huic M, Pitter JG, Vogt V, Stokes J1, Baltaxe E. Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA). BMC Health Serv Res. 2018 Jul 24;18(1):576. Link

Nemeth B. Health Economics in Hungary: Great potential, missed opportunity? [in Hungarian]  LAM (Lege Artis Medicinæ) - 2018;28(06-07) Link 

Csanadi M, Kalo Z, Prins CPJ, Grelinger E, Menczelne Kiss A, Fricke FU, Fuksa L, Tesar T, Manova M, Lorenzovici L, Voko L, Garrison LP. The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy and Technology. 2018. 7(3): 243-250 Link

Leijten FRM, Hoedemakers M, Struckmann V, Kraus M, Cheraghi-Sohi S, Zemplényi A, Ervik R, Vallvé C, Huiĉ M, Czypionka T, Boland M, Rutten-van Mölken MPMH; SELFIE consortium. Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. BMJ Open. 2018 Aug 30;8(8):e021072. doi: 10.1136/bmjopen-2017-021072. Link

Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, Nemeth B, Maniadakis N, Brixner D, Wijaya K, Kalo Z.Guidance toward the implementation of multicriteria decision analysis framework in developing countries. Expert Review of Pharmacoeconomics & Outcomes. [Epub ahead of print] Link

Agh T, Gaspar K, Nagy B, Lehmann M, Kalo Z. The value of a child born in the European Union. Acta Oeconomica. 2018; 68(2): 295-309 Link

Pitter JG, Voko Z, Jozwiak A, Berkics A. Campylobacter control measures in indoor broiler chickencritical re-assessment of cost-utilityand putative barriers to implementation. Epidemiol Infect. 2018 Jun 27:1-12. doi: 10.1017/S0950268818001528. Link

Gyulai A, Nagy A, Pataki V, Tonte D, Adany R, Voko Z. General practitioners can increase participation in cervical cancer screening - a model program in Hungary. BMC Fam Pract. 2018 May 19;19(1):67. doi: 10.1186/s12875-018-0755-0. Link

Zelei T, Csetneki K, Vokó Z, Siffel C. Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet J Rare Dis. 2018 Apr 10;13(1):53. doi: 10.1186/s13023-018-0796-4. Link

Csanadi M, Loblova O, Ozieranski P, Harsanyi A, Kalo Z, McKee M, King L. When health technology assessment is confidential and experts have no power: the case of Hungary. Health Econ Policy Law. 2018 Mar 26:1-20. Link

Kulchaitanaroaj P, Kalo Z, West R, Cheung KL, Evers S, Voko Z, Hiligsmann M, de Vries H, Owen L, Trapero-Bertran M, Leidl R, Pokhrel S. Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. BMC Health Services Research. 2018. 14.18(1):115. Link

Kovacs G, Almasi T, Millier A, Toumi M, Horvath M, Koczian K, Gotze A, Kalo Z, Zemplenyi AT. Direct healthcare cost of schizophrenia–European overview. European Psychiatry. 2018. 48. 79-92. Link

Zemplenyi AT, Kalo Z, Kovacs G, Farkas R, Beothe T, Banyai D, Sebestyen Z, Endrei D, Boncz I, Mangel L. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl). 2018. 27. e12430 Link

Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z. Patient access, Unmet medical need, Expected benefits and concerns related to the utilisation of biosimilars in Eastern European Countries: A survey of experts. BioMed Research International. 2018. 9597362. 9. Link

Nemeth B, Jozwiak-Hagymasy J, Kovacs G, Kovacs A, Demjen T, Huber M, Cheung KL, Coyle K, Lester-George A, Pokhrel S, Voko Z.Cost-effectiveness of possible future smoking cessation strategies in Hungary: results from the EQUIPTMOD. Addiction, doi: 10.1111/add.14089. Link

Nemeth B, Fasseeh A, Molnar A, Bitter I, Horvath M, Kóczián K, Gotze A, Nagy B. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2018 Jan 27:1-9. doi: 10.1080/14737167.2018.1430571. Link

Nemeth B, Kulchaitanaroaj P, Lester-George A, Huic M, Coyle K, Coyle D, Pokhrel S, Kalo Z. A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study. Addiction, doi: 10.1111/add.14092. Link

Pitter, J. G., Lukacs, G., Csanadi, M. and Voko, Z. (2018), Clinical impact of treatment delay in pancreatic cancer patients revisited. Int. J. Cancer. doi:10.1002/ijc.31263 Link



Tesar T, Szilberhorn L, Nemeth B, Nagy B, Wawruch M, Kalo Z. Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. Frontiers in Pharmacology. 2017. 8. 946. Link

Voko Z, Gaspar K, Inotai A, Horvath Cs, Bors K, Speer G, Kalo Z. Osteoporotic fractures may impair life as much as the complications of diabetes. Journal of Evaluation in Clinical Practice. 2017. 23. 6. 1375-1380. Link

Narbutas Š, York K, Stein BD, Magsanoc-Alikpala K, Majima Y, Kalo Z, Almasi T, Inotai A. Overview on patient centricity in cancer care. Frontiers in Pharmacology. 2017. 5. 8. 698. Link

Nagy B, Setyawan J, Coghill D, Soroncz-Szabo T, Kalo Z, Doshi JA. A conceptual framework for a long-term economic model of the treatment of attention-deficit/hyperactivity disorder. Expert Rev Pharmacoecon Outcomes Res. 2017. 17. 3. 283-292. Link

Kalo Z, Abonyi-Toth Zs, Rokszin Gy, Agh T, Inotai A. Impact of multiple switching on health care costs and outcomes in generic drug policies: the Hungarian case of losartan. Acta Poloniae Pharmaceutica - Drug Research, 2017. 74. 4. 1295-1300. Link

Kalo Z, Voko Z, Ostor A, Clifton-Brown E, Vasilescu R, Gibson E, Begum N. Patient access to reimbursed biologic disease modifying antirheumatic drugs in the European region. Journal of Market Access & Health Policy. 2017. 5. 1. 1345580. Link

Brixner D, Maniadakis N, Kalo Z, Hu S, Shen J, Wijaya K. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an evidence-based HTA methodology for evaluating off-patent pharmaceuticals (OPPs) in emerging markets. Value in Health Regional Issues. 2017. 13. 1-6. Link

Rosselli D, Lazo CQ, Csanadi M, Ruiz de Castilla EM, González NC, Valdés J, Abicalaffe C, Garzón W, Leon G, Kalo Z. HTA implementation in Latin American countries: Comparison of current and preferred status. Value in Health Regional Issues. 2017. 14. 20-27. Link

Inotai A, Csanadi M, Harsanyi A, Nemeth B. Drug Policy in Central Eastern Europe—Hungary. Value in Health Regional Issues. 2017.13:16-22 Link

Inotai A, Csanadi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P, Kaló Z. Policy Practices to Maximise Social Benefit from Biosimilars. Bioequiv Availab 2017.9 (4):467-472 Link

Inotai A, Prins CPJ, Csanádi M, Vitezic D, Codreanu C, Kalo Z. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017.17(8):915-926. Link

Voko Z, Barra M, Molnar A, Kerpel-Fronius A, Bajzik G, Horvath I, Moizs M, Nagy B. Model concept of the health economic evaluation of low-dose CT lung cancer screening in Hungary. [in Hungarian] DOI: 10.1556/650.2017.30731 Orvosi Hetilap 2017.158.25. Pages 963–975. Link

Nemeth B, Molnar A, Akehurst R, Horvath M, Koczian K, Nemeth G, Gotze A, Voko Z. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017 May 17. doi: 10.2217/cer-2017-0024. Link

Elek P, Harsanyi A, Zelei T, Csetneki K, Kalo Z. Policy objective of generic medicines from the investment perspective: The case of clopidogrel. Health Policy Volume 121, Issue 5, May 2017, Pages 558–565. Link

Elek P, Takacs E, Meresz G, Kalo Z. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.Health Policy Plan. 2017. 1;32(3). 349-358. Link

Nemeth B, Csanadi M, Kalo Z.  Overview on the current implementation of health technology assessment in the healthcare system in Hungary. International Journal of Technology Assessment in Health Care, 33:1 (2017), Page 1 of 6. Link

Kovacs G, Somogyvari Z, Maka E, Nagyjanosi L. Bedside ROP screening and telemedicine interpretation integrated to a neonatal transport system: Economic aspects and return on investment analysis. Early Hum Dev. 2017 Feb 4;106-107:1-5. doi: 10.1016/j.earlhumdev.2017.01.007. Link

Coyle K, Coyle D, Lester‐George A, West R, Nemeth B, Hiligsmann M, Trapero‐Bertran M, Leidl R, Pokhrel S. Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. Addiction. 2017 Aug 18. Link

Trapero‐Bertran M, Muñoz C, Coyle K, Coyle D, Lester‐George A, Leidl R, Németh B, Cheung KL, Pokhrel S, Lopez‐Nicolás Á. Cost‐effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. Addiction. 2017. Link

Huber MB, Präger M, Coyle K, Coyle D, Lester‐George A, Trapero‐Bertran M, Nemeth B, Cheung KL, Stark R, Vogl M, Pokhrel S. Cost‐effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. Addiction. 2017 Dec 15. Link

Pitter G Janos , Horvath B, Abonyi-Toth Zs, Rokszin Gy, Fadgyas-Freylere P, , Kovacs G, Acs N, Kaló Z, Voko Z. Drug-associated miscarriage, teratogenicity and low birthweight risks: Methods for population-based case–control studies in Hungary. Reproductive Toxicology 72: P. 26. (2017) Link

Kalo Z, Voko Z, Ostor A, Clifton-Brown E, Vasilescu R , Battersby A, Gibson E. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. Journal of Market Access & Health Policy 5:(1) Paper 1345580. 8 p. (2017) Link

Ozieranski P, Loblova O, Nicholls N, Csanadi M, Kalo Z, McKee M, King L. Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015. Health Econ Policy Law. 2018 Jan 8:1-23. Link 



Nagy B, Zsolyom A, Nagyjanosi L, Meresz G, Steiner T, Papp E, Dessewffy Z, Jermendy G, Winkler G, Kalo Z, Voko Z. Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. 2016 Oct;32(7):710-729. doi: 10.1002/dmrr.2791. 2016 May 1. Link

Kolasa K, Zah V, Kalo Z. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations. Expert Rev Pharmacoecon Outcomes Res. 2016. 16(4). 483-8. Link

Voko Z, Zsolyom A, Jermendy Gy. Diabetes attributable mortality in Hungary in 2000-2009.[in Hungarian] Lege Artis Medicinae 2016;26:265-270. Link

Kovacs G, Zelei T, Voko Z. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. Climacteric, 2016, 1-8. Link

Zelei T, Molnar MJ, Szegedi M, Kalo Z. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet Journal of Rare Diseases, 2016, 11:(1) p. 72. Link

Inotai A, Csanadi M, Agh T. Real world data analysis to improve drug policy decision making in Central Eastern European countries. [in Hungarian] IME Interdiszciplináris Magyar Egészségügy, 2016, 15: 47-52. Link

Voko Z, Turi G, Zsolyom A. Cost-effectiveness of oral cancer screening in Hungary. [in Hungarian] Orv. Hetil., 2016, 157(29), 1161–1170. Link

Voko Z, Cheung KL, Jozwiak-Hagymasy J, Wolfenstetter S, Jones T, Munoz C, Evers SMAA, Hiligsmann M, de Vries H, Pokhrel S. Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. Health Research Policy and Systems 2016, 14:38 Link

Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Lohner S, Boncz I. Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer (Article in Hungarian). Orv Hetil. 2016.157(20):776-88. Link

Marsh K, IJzerman M, Thokala,P, Baltussen R, Boysen,M, Kalo,Z, Lönngren T, Mussen, F, Peacock S, Watkins J, Devlin N. Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016. 19(2). 125–137. Link

Kolasa K, Zwolinski KM, Hermanowski T, Kalo Z. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) into the Polish pricing and reimbursement process of orphan drugs. Orphanet Journal of Rare Diseases, 2016. 10;11(1):23. Link

Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Boncz I. A microcosting study of radiation therapy of localized prostate cancer. Orv Hetil. 2016. 157. 12. 461-8 (in Hungarian) Link

Agh T, Kovacs G, Supina D, Pawaskar M, Herman BK, Voko Z, Sheehan DV. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eating and Weight Disorders. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, September 2016, Volume 21, Issue 3, pp 353–364 Link

Agh T, Pawaskar M, Nagy B, Lachaine J, Voko Z. The cost-effectiveness of lisdexamfetamine dimesylate for the treatment of binge eating disorder in the United States. Clinical Drug Investigation 36(4):305-312. Link

Bodnar R, Meszaros A, Olah M, Agh T. Inhaled antibiotics for the treatment of chronic Pseudomonas Aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes. Patient Preference and Adherence. 2016. 10:183-193. Link

Cheung KL, Evers SM, Hiligsmann M, Voko Z, Pokhrel S, Jones T, Muñoz C, Wolfenstetter SB, Jozwiak-Hagymasy J, de Vries H. Understanding the stakeholders' intention to use economic decision-support tools: A cross-sectional study with the tobacco return on investment tool. Health Policy. 2016 Jan;120(1):46-54. Link

Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T, Mussen F, Peacock S, Watkins J, Ijzerman M. Multiple Criteria Decision Analysis for Health Care Decision Making-An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016. 19. 1. 1-13. Link

Kalo Z, Gheorghe A, Huic M, Csanadi M, Kristensen FB. HTA Implementation Roadmap in Central and Eastern European Countries. Health Econ. 2016 Feb;25 Suppl 1:179-92. Link



Mandrik O, Knies S, Kalo Z, Severens JL. Reviewing transferability in economic evaluations originating from Eastern Europe. Int J Tech Assess Health Care, 2015. 31. 6. 434–441. Link

Drummond M, Augustovski F, Kalo Z, Yang BM, Pichon-Riviere A, Bae EZ, Kamal-Bahl S. Challenges faced in transferring economic evaluations to middle income countries. Int J Technol Assess Health Care. 2015. 31. 6. 442-8. Link

Pitter J, Jozwiak A, Martos E, Kalo Z, Voko Z. Next steps to evidence-based food safety risk analysis: opportunities for health technology assessment methodology implementation. Studies in Agricultural Economics 2015. 117. 155-161. Link

Bartfai Z, Agh T, Domotor P, Bartfai L, Meszaros A. Therapeutic opportunities derived from clinical differences among inhaled corticosteroids. [in Hungarian] Medicina Thoracalis, 5:339-344.

Oyebode O, Garrett Z, George E, Cangini A, Muscolo LA, Warren S, Nemeth B, Foldesi C, Heislerova M, Gajdosova E. Evidence requirements for reimbursement of pharmaceuticals across Europe. Int J Technol Assess Health Care. 2015 Jan;31(1-2):59-67. Link

Kalo Z, Alabbadi I, Al Ahdab OG, Alowayesh M, Elmahdawy M, Al-Saggabi AH, Tanzi VL, Al-Badriyeh D, Alsultan HS, Ali FM, Elsisi GH, Akhras KS, Voko Z, Kanavos P. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2015 Dec;15(6):993-8. Link

Inotai A, Abonyi-Toth Z, Rokszin G, Voko, Z. Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. Value in Health Regional Issues 2015;7:1-8. Link

Sebestyen A, Mester S, Voko Z, Gajdacsi J, Cserhati P, Speer G, Patczai B, Warta V, Bodis J, Horvath C, Boncz I. Wintertime surgery increases the risk of conversion to hip arthroplasty after internal fixation of femoral neck fracture. Osteoporos Int 2015;26(3):1109-1117. Link

Agh T, Peterne D, Bartfai Z., Inotai A, Fujsz E, Meszaros A. (2015) Relationship between medication adherence and health related quality of life in patients with COPD: a systematic review. Respiratory Care. 60:297-303 Link

Kolasa K, Kalo Z, Hornby E. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. Expert Rev Pharmacoecon Outcomes Res, 2015. 15. 1. 145-55. Link

Kalo Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Agh T, Inotai A, Brixner D. Need for Multicriteria Evaluation of Generic Drug Policies, Value in Health, 2015. 18. 346-351. Link

Nagy B: Improving the allocation of health care resources in Poland. World Health Organization Regional Office for Europe. Copenhagen, 2015 Link

Jozwiak-Hagymasy J, Voko Z: Use of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus panel [in Hungarian] IME 2015; 14:1 48:53 Link

Voko Z, Beran D, Pusztai Zs, Bak Pedersen H, Evetovits T, Szigeti Sz. Better non-communicable disease outcomes: challenges and opportunities for health systems. Hungary Country Assessment: Focus on diabetes 2014. WHO Regional Office for Europe Link

Agh T, Kovacs G, Pawaskar M, Supina D, Inotai A, Voko Z. (2015) Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. Eating and Weight Disorders. 20:1-12. Link

Pawaskar M , Agh T , Radewonuk J , Voko Z , McElroy S L , Herman B K , Gasior M. Longitudinal modeling of the relationship between lisdexamfetamine dimesylate and health-related quality of life in adults with moderate to severe binge eating disorder. Value in Health 18:(7) p. A407. 2015 Link



Meresz G., Foldesi Cs., Nagyistok Sz., Vincziczki A.: Changes on the market of publications and a dynamising health economic researcher community [in Hungarian]. Egeszsegugyi Gazdasagi Szemle 2014/2-3, p36-41. Link

Pokhrel S, Evers S, Leidl R, Trapero-Bertran M, Kalo Z, Vries Hd, Crossfield A, Andrews F, Rutter A, Coyle K, Lester-George A, West R, Owen L, Jones T, Vogl M, Radu-Loghin C, Voko Z, Huic M, Coyle D. EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. BMJ Open. 2014 Nov 24;4(11):e006945. doi: 10.1136/bmjopen-2014-006945. PubMed PMID: 25421342. Link

Kalo Z, Antal J, Penzes M, Pozsgay C, Szepezdi Z, Nagyjanosi L. Contribution of clinical trials to gross domestic product in Hungary. Croat Med J. 2014 Oct 30;55(5):446-51. PubMed PMID: 25358877. Link

Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Voko Z, Yabe D, Bluher M, Paldanius PM. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014 May 27. pii: S0168-8227(14)00219-8. doi: 10.1016/j.diabres.2014.05.005.  Link

Voko Z, Nemeth R, Nagyjanosi L, Jermendy Gy, Winkler G, Hidvegi T, Kalotai Z, Kalo Z. Mapping the Nottingham Health Profile onto the Preference-Based EuroQol-5D Instrument for Patients with Diabetes. Value in Health Regional Issues. 2014. 4. 1. 31-36 Link

Elsisi GH, Eldessouki R, Kalo Z, Elmazar MM, Taha AS, Awad BF, El-Hamamsy MH. Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. Value in Health Regional Issues. 2014. 4. 1. 24-30. Link

Kalo Z, Boncz I, Dank M, Koczian K, Molnar MJ, Nagy B, Nemeth Gy, Pitter J, Zelei T. Health Economic Aspects of Personalized Medicine: Do Personalized Technologies Reduce Health Expenditure? [in Hungarian] IME. 2014. 13. 5. 41-45. Link

Kwong D, Ferrario A, Adamski J, Inotai A, Kalo Z. Managing the Introduction of New and High-Cost Drugs in Challenging Times: The Experience of Hungary and Poland. Eurohealth. 2014. 20. 2. 25-28. Link

Adany R; Voko Z. Hungarian public health - ups and downs in the last 20 years. Eu J Pub Health 2014; doi: 10.1093/eurpub/cku034 Link

Inotai A, Petrova G, Vitezic D, Kalo,Z. Benefits of investment into modern medicines in Central Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2014. 14. 1. 71-79. Link

Kovacs G, Kalo Z, Jahnz-Rozyk K, Kyncl J, Csohan A, Pistol A, Leleka M, Kipshakbaev R, Durand L, Macabeo B. Medical and economic burden of influenza in the elderly population in central and eastern European countries. Human Vaccines and Immunotherapeutics. 2014. 10. 2. 1-13. Link

Nagy B, Timar G, Jozwiak-Hagymasy J, Kovacs G, Meresz G, Vamossy I, Agh T, Laszlo A, Voko Z, Kalo Z. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2014 175. 75-81.  Link



Szabo L, Jackowska T, Kalo Z, Kulcsar A, Meszner Zs, Molnar Zs, Wysocki J, Wutzler P, Kormos-Tasi J, Sauboin C. Varicella vaccination in Hungary and Poland: optimization of public benefits from prophylaxis technologies in the time of austerity. New Medicine. 2013. 3. 97-102. Link

Voko Z, Nemeth R, Dank M, Nagy-Erdei Zs, Kalo Z, Geczi L: Mapping the cancer-specific EORTC QLQ-BR23 onto the preference-based EuroQol-5D instrument. JHPOR 2013, 6 Link

Voko Z, Inotai A, Horvath Cs, Bors K, Speer G, Kalo Z: Quality of Life of Patients With Osteoporosis In Hungary. [in Hungarian] LAM KID - 2013;3(4) Link

Orosz E, Meresz G, Nagy B: Investment to human capital: fallback from the developed countries? [in Hungarian] Educatio, Volume 22, Number 2, 2013., p159-176. Link

Meresz G, Nemeth B, Sinkovits B: VII. IME-META Advanced Training and Conference on Health Economics: „Is the crisis an opportunity or a curse?” Conference Report. Acta Oeconomica Volume 63, Number 3, September 2013., p377-381. Link

Kalo Z, Annemans L, Garrison LP: Differential pricing of new pharmaceuticals in lower income European countries. Expert Review of Pharmacoeconomics & Outcomes Research,2013. 13. 6. 735-41. Link

Elsisi GH, Kalo Z, Eldessouki R, Elmahdawy MD, Saad A, Ragab S, Elshalakani AM, Abaza S: Recommendations for reporting pharmacoeconomic evaluations in Egypt. Value in Health Regional Issues, 2013. 2. 2. 319 -327. Link

Kalo Z, Bodrogi J, Boncz I, Dozsa Cs, Jona G, Kovi R, Pasztelyi Z, Sinkovits B: Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary. Value in Health Regional Issues, 2013. 2. 2. 264-266. Link

Szabo RP, Klenk N, Balla J, Asztalos L, Szabo L, Voko Z: Prognosis of dialysed patients after kidney transplant failure. Kidney Blood Press Res 2013;37:151-157. Link

Agh T, Meszaros A, Bartfai Z: Quality of life and adherence in chronic obstructive pulmonary disease [in Hungarian]. MedicaOnline Link



Borsos G, Voko Z, Gredes T, Kunert-Keil C, Vegh A: Tooth movement using palatal implant supported anchorage compared to conventional dental anchorage. Ann Anat. 2012 Sep 20 Link

Inotai A, Agh T, Meszaros A: Quality of life, utility and health burden in asthma, chronic obstructive pulmonary disease and rheumatoid arthritis. International Journal of Person Centered Medicine, 2012. 2: 505-510. Link

Inotai A, Kalo Z: Risk sharing methods in middle income countries [in Hungarian]. Acta Pharm Hung (Acta Pharm Hung), 2012; 82: 43-52. Link

Inotai A, Meszaros A: Determinants of nsaid choice in rheumatoid arthritis - a drug utilization study. Acta Pol Pharm, 2012. 69: 773-777. Link

Inotai A, Nagy B, Kalo Z: Biosimilars and evidence based decision making in Central Eastern European countries. [in Hungarian] Orvostovabbkepző Szemle, 2012. 19: 69-73. Link

Inotai A, Nuijten M, Roth E, Hegazi R, Kalo Z: Modelling the burden of disease associated malnutrition. e-SPEN Journal, 2012. 7. e196-e204 Link

Inotai A, Pekli M, Jona G, Nagy O, Remak E, Kalo Z: Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. BMC Health Serv Res. 2012. 21. 12. 1. 332. Link

Kalo Z, Abonyi-Toth Zs, Bartfai Z, Voko Z: Pitfalls associated with the therapeutic reference pricing practice of asthma medication, BMC Pulmonary Medicine, 2012 20. 12. 1. 35 Link

Kalo Z, Boncz I, Inotai A: Implications of economic crisis on health care decision-making in Hungary: An opportunity to change? Journal of Health Policy and Outcomes Research, 2012. 1. 20 -26. Link

Kalo Z, Landa K, Doležal T, Voko Z: Transferability of NICE recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries, European Journal of Cancer Care, 2012. 21. 4. 442-449. Link

Kalo Z, Meresz G, Mezei D, Totth A, Inotai A: The grounding and implications of Szell Kalman Plan [in Hungarian]. IME Az egeszsegugyi vezetők szaklapja, 2012; 11:6 12-16. Link

Kalo Z, Nagy B: Methodological questions in assessing the cost effectiveness of prevention programs. [in Hungarian] Egeszsegugyi Gazdasagi Szemle 2012; 50:1 29-31 Link

Kolasa K, Kalo Z, Zah V, Dolezal T: The role of HTA in the process of implementation of EU Transparency Directive: a relevant experience from Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research, 2012 12. 3. 283-7. Link

Meresz G, Kalo Z, Tabak A: Cost minimisation analysis of basal insulin analogues for treatment of type 2 diabetes. [in Hungarian] Lege Artis Medicinae, 2012;22(12):669–676. Link

Nagy B, Nagyjanosi L, Nagyistok Sz, Jozwiak-Hagymasy J, Meresz G, Papp E, Dessewffy Z, Jermendy GY, Winkler G, Kalo Z, Voko Z: Health economic modell to assess the screening, treatment and management strategies of diabetes. [in Hungarian] Diabetologia Hungarica, 2012. 20.4 p.245-255 Link

Nagy B, Gaspar I, Papp A, Bene Z, Nagy B, Voko Z, Balla G: Efficacy of methylprednisolone in children with severe community acquired pneumonia. PEDIATRIC PULMONOLOGY Volume 48, Issue 2 February 2013 Pages 168–175 (2012) Link

Nagy B, Meresz G: Role of risk-sharing in health care. [in Hungarian] Egeszsegugyi Gazdasagi Szemle, 2012 November 1; 50(4): 42-48. Link

Papp K, Vegh P, Hobor R, Szittner Z, Voko Z, Podani J, Czirjak L, Prechl J: Immune Complex Signatures of Patients with Active and Inactive SLE Revealed by Multiplex Protein Binding Analysis on Antigen Microarrays. PLoS One. 2012;7(9):e44824. Link

Petrovski B E, Pataki V, Jenei T, Adany R, Voko Z: Selenium levels in men with liver disease in Hungary. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY 26:(1) pp. 31-35. (2012) Link

Szigethy E, Szeles G, Horvath A, Hidvegi T, Jermendy G, Paragh G, Blasko G, Adany R, Voko Z: Epidemiology of the metabolic syndrome in Hungary PUBLIC HEALTH 126:(2) pp. 143-149. (2012) Link

Voko Z, Nagyjanosi L, Kalo Z: Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary, BMC Public Health, 2012. 12. 1. 924. Link

Voko Z, Nagyjanosi L, Margitai B, Kovi R, Toth Z, Laszlo D, Kalo Z: Modeling cost-effectiveness of cervical cancer screening in Hungary. Value in Health 2012. 15. 39-45. Link

Walter S, Mackenbach J, Voko Z, Lhachimi S, Ikram MA, Uitterlinden AG, Newman AB, Murabito JM, Garcia ME, Gudnason V, Tanaka T, Tranah GJ, Wallaschofski H, Kocher T, Launer LJ, Franceschini N, Schipper M, Hofman A, Tiemeier H: Genetic physiological, and lifestyle predictors of mortality in the general population. AMERICAN JOURNAL OF PUBLIC HEALTH 102:(4) pp. e3-10. (2012) Link

Meszaros A, Agh T, Bartfai Z, Orosz M: Quality of life decrement and health burden in asthma and COPD [in Hungarian]. Medicina Thoracalis, 2012, 65: 219.



Nemeth J, Nagyjanosi L, Nagyistok Sz, Tolnayne Csattos M, Szabone Berta I, Kincse E, Szulyak E, Boer I, Hundzsa Gy, Kalo Z, Berta A: Societal burden of blindness in Hungary [in Hungarian] LAM (Lege Artis Medicinæ) - 2011;21(10) Link

Agh T, Inotai A, Meszaros A: Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration, Available online DOI: 10.1159/000324453 Link

Gorog K, Pattenden S, Antova T, Niciu E, Rudnai P, Scholtens S, Splichalova A, Slotova K, Voko Z, Zlotkowska R, Houthuijs D: Maternal Smoking During Pregnancy and Childhood Obesity: Results from the CESAR Study. MATERNAL CHILD HEALTH JOURNAL 15: pp. 985-992. (2011) Link

Inotai A, Meresz G, Kalo Z: Assessment of Hungarian pharmaceutical expenditures with respect to Szell Kalman Plan [in Hungarian]. Egeszsegugyi Gazdasagi Szemle 2011; 49: 9-13. Link

Inotai A, Rojkovich B, Fulop A, Jaszay E, Agh T, Meszaros A: Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int. 2011 Jan 18. Link

Kalo Z, Voko Z: Health technology assessment: a European collaboration. Meeting report. Expert Rev. Pharmacoeconomics Outcomes Res. 2011. 11.1. 41-43. Link

Losonczy G, Fekete A, Voko Z, Takacs L, Kaldi I, Ajzner E, Kasza M, Vajas A, Berta A, Balogh I: Analysis of complement factor H Y402H, LOC387715, HTRA1 polymorphisms and ApoE alleles with susceptibility to age-related macular degeneration in Hungarian patients ACTA OPHTHALMOLOGICA 89:(3) pp. 255-262. (2011) Link

Nagy B, Brennan A, Brandtmuller A, Thomas S, SD Sullivan, R Akehurst: Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in UK using MMSE- and ADL-based models, International Journal of Geriatric Psychiatry, 2011 26:5 483-94 Link

Ohmann C, Kuchinke W, Canham S, Lauritsen J, Salas N, Schade-Brittinger C, Wittenberg M, McPherson G, McCourt J, Gueyffier F, Lorimer A, Torres F, Collaborator: Voko Z: Standard requirements for GCP-compliant data management in multinational clinical trials. TRIALS 12: p. 85. (2011) Link

Papp K, Vegh P, Hobor R, Szittner Z, Voko Z, Podani J, Koranyi KL, Czirjak LK, Prechl J: Functional serum antibody profiles in autoimmune disease diagnostics MOLECULAR IMMUNOLOGY 48:(14) p. 1732. (2011) Link

Petrovski B E, Szeles G, Melles M, Pataki V, Kardos L, Jenei T, Adany R, Voko Z: Behaviour does not fully explain the high risk of chronic liver disease in less educated men in Hungary EUROPEAN JOURNAL OF PUBLIC HEALTH 21:(5) pp. 662-666. (2011) Link

Rojkovich B, Inotai A: Cardiovascular safety of nonsteroidal antiinflammatory drugs [in Hungarian]. Lege Artis Medicinae, 2011; 21: 123-125. Link

Szabo RP, Asztalos L, Szabo L, Balla J, Voko Z: Validation of a prognostic function for renal transplant recipients in Hungary JOURNAL OF NEPHROLOGY 24:(5) pp. 619-624. (2011) Link

Voko Z: Potentials of payers' databases for pharmacoepidemiological investigations basic clinical pharmacology toxicology 109:(1) p. 21. 1 p. (2011)

Voko Z, de Brouwer S, Lubsen J, Danchin N, Otterstad JE, Dunselman PH, Kirwan BA: Long-term impact of secondary preventive treatments in patients with stable angina. EUROPEAN JOURNAL OF EPIDEMIOLOGY 26: pp. 375-383. (2011) Link

Meszaros A, Szabo L, Agh T, Fujsz E, Bartfai Z: Measurement of health related quality of life and asthma control in Hungary [in Hungarian]. Tudőgyogyaszat 2011, 5: 28-31. Link



Agh T, Meszaros A: Compliance and persistence with medications for chronic obstructive pulmonary disease. Clinical and Experimental Medical Journal. 4: 15-22. Link

Bodrogi J, Kalo Z: Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010. 159. 7. 1367-73. Link

Inotai A, Hanko B, Meszaros A: Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol Drug Saf, 19: 183-190, 2010. Link

Inotai A, Kalo Z: The assessment of innovation and the R&D&I strategy of public health care sector [in Hungarian]. Egeszsegugyi Gazdasagi Szemle, 2010; 48: 33-38. Link

Inotai A, Meresz G, Kalo Z: Assessment of the pharmaceutical expenditure in Hungary [in Hugarian]. Acta Pharm Hung, (Acta Pharm Hung) 2010; 80: 162-172. Link

Inotai A, Rojkovich B, Meszaros A: The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary-a cross sectional non interventional study [in Hungarian] Acta Pharm Hung, (Acta Pharm Hung) 2010; 80: 47-54. Link

Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, Voko Z, Gaynor S, Cooney M, Doran P, Maggioni A, Lorimer A, Torres F, McPherson G, Charwill J, Hellstrom M, Lejeune S: Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres TRIALS 11: Paper 79. (2010) Link

Nagy B: Resource allocation in Hungarian health care - Is there a missing link? [in Hungarian]. Kozgazdasagi Szemle (Journal of Economic Literature) 2010; 57:4 337-353 Link

Voko Z, Danchin N, de Brouwer S, Kirwan BA, Poole-Wilson PA, Lubsen J: Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: The ACTION experience INTERNATIONAL JOURNAL OF CARDIOLOGY 138:(1) pp. 56-62.(2010) Link

Agh T, Bodnar R, Agh L: The importance of quality of life monitoring in the management of asthma [in Hungarian]. Medicus Universalis, 2010 43: 179-181. Link

Orosz M, Galffy G, Kovacs D, Agh T, Meszaros A: Quality of life, possible influential factors of asthmatics and COPD patients [in Hungarian]. Medicina Thoracalis, 2010 63: 277-283.

Agh T, Meszaros A: Pharmacoeconomic impact of compliance [in Hungarian]. Acta Pharmaceutica Hungarica, 2010, 80: 75-80. Link

Orosz M, Galffy G, Agh T, Kovacs D, Meszaros A: The everyday life of patients with asthma or COPD. [in Hungarian]. Medicina Thoracalis, 2010, 63: 181-182.

Agh T, Bartfai Z, Meszaros A: Relation of adherence to quality of life in COPD patients. [in Hungarian]. Medicina Thoracalis, 2010, 63: 197.



Inotai A, Kalo Z Meszaros A: Decision analytic modeling and their impact on health care decision making [in Hungarian], Acta Pharm Hung, (Acta Pharm Hung) 2009; 79: 63-69. Link

Inotai A, Meszaros A: Economic evaluation of NSAID strategies in rheumatoid arthritis. Cost-effectiveness of celecoxib in Hungary. Int J Technol Assess Health Care, 25: 190-195 Link

Nagy B, Brandtmuller A, Dozsa Cs: The Redistributive Role of the State in the British and Dutch Health Care Market. Is there another Way? [in Hungarian] Tarsadalomkutatas (Social Science Research) 2009; 27: 2117-2138 Link

Nagy B, Brennan A, Skultety L, Nagy J, Szentesi A, Dessewffy Z, Kalotai Z: The cost effectiveness of rivastigmine transdermal patch in the management of patients with mild and moderate Alzheimer’s disease [in Hungarian]. IME, 2009; 8:3 40-45 Link

Voko Z, Csepe P, Nemeth R, Kosa K, Kosa Zs, Szeles Gy, Adany R: Does socioeconomic status fully mediate the effect of ethnicity on the health of Roma people in Hungary? JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 63:(6) pp. 455 460. (2009) Link

Voko Z, Nagyjanosi L, Kalo Z: Direct health care costs of diabetes mellitus in Hungary [in Hungarian], Lege Artis Mediciane, 2009;19(12):775-780 Link

Agh T, Meszaros A: Compliance and persistence with medication in chronic obstructive pulmonary disease [in Hungarian]. Orvosi Hetilap 2009, 150: 1497-1502. Link

Agh T, Agh L: The significance of medication compliance and persistence in hypertension, diabetes mellitus and dyslipidaemia [in Hungarian]. Medicus Universalis, 2009, 42: 3-6. Link



Bhalla A, Grieve R, Rudd AG, Wolfe CD, BIOMED II ESSC, 44 Authors, Voko Z, Ovary C: Stroke in the Young: Access to Care and Outcome; A Western Versus Eastern European Perspective JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES 17:(6) pp. 360-365. (2008) Link

Inotai A, Meszaros A: Cost effectiveness of celecoxib in rheumatoid arthritis [in Hungarian], IME, 2008; 7: 48-50 Link

Inotai A, Vincze Z: Cost study of NSAID use in rheumatoid arthritis based on recent therapeutic protocols [in Hungarian], Acta Pharm Hung (Acta Pharm Hung), 2008; 78: 79-86. Link

Nagy B, Brandtmuller A: Implementing risk adjusted capitation payments with health care reforms in Hungary, Competitio, 2008; 8:2 147-160 Link

Nagy B, Rakonczai P, Gulacsi L: Application of statistical methods to calculate capitation payments in the Hungarian health care. [in Hungarian] Statisztikai Szemle (Hungarian Statistical Review) 2008; 86:4 321-341 Link

Nagy B, Rakonczai P, Sipos J: Predicting health care expenditures with demographic characteristics for designing capitation payments in Hungary [in Hungarian]. IME 2008; 7:Egeszseg-gazdasagtani kulonszam 5-9 Link

Takemoto SK, Arns W, Bunnapradist S, Garrison LP, Guirado L, Kalo Z, Oniscu G, Opelz G, Scolari MP, Stefoni S, Yaqoob M, Brennan DC: Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research ,Transplantation, 2008. 86.1. 18-25. Link




Syreon Research Institute: 1142 Budapest, Mexikoi str. 65/A.